Fundraising Fox
/Companies
Sign in

Rani Therapeutics Holdings

NASDAQ: RANI

San Jose, US · Founded 2021 · California corporation · 2 known investors

Find your way into Rani Therapeutics Holdings

288 people in our graph share verified history with the Rani Therapeutics Holdings team — schools, employers, funds. One of them is your warm intro.

Robert DeBenedettounlockedknows Svai Sanford · together at SFJ Pharmaceuticals, Inc. (overlapped)
knows the team · via SFJ Pharmaceuticals, Inc.
knows the team · via Rani Therapeutics
knows the team · via Novellus Systems acquired by Lam Research Corporation
×4knows the team · via Glam Media, Inc.
×4knows the team · via Elan Pharmaceuticals, Inc.

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for biologics and drugs, primarily through its proprietary RaniPill capsule platform, which comes in two configurations (RaniPill GO for up to 3 mg microtablet doses and RaniPill HC for up to 200µL liquid doses). The company is advancing a pipeline of oral therapeutic candidates internally and through collaborations with third-party biopharmaceutical companies, including RT-114 (a GLP-1/GLP-2 dual agonist for obesity) in Phase 1 trials and RT-117 (an antibody for hemophilia) in collaboration with Chugai Pharmaceutical.

Biotech

Founders & leadership

TITalat Imran
Talat ImranExecutiveTalat Imran is Chief Executive Officer and director of Rani Therapeutics, a clinical-stage biopharmaceutical company developing oral delivery technologies for biologics. He previously held managing director positions at InCube Ventures and VHM Ventures, and holds a bachelor's degree in computer science.
SSSvai Sanford
Svai SanfordExecutiveSvai Sanford has held financial leadership roles including director, controller, VP, and CFO positions, with experience in strategic planning, fundraising, SEC compliance, and IPO preparation across publicly traded and development-stage biopharmaceutical companies.
MHMir Hashim
Mir HashimExecutive

Board

AB
Abraham BassanBoard director
VB
Vasudev Bailey, M.D.Board director
MIMir Imran
Mir ImranBoard directorInvestor at InCube Ventures
JB
Jean-Luc ButelBoard director
LR
Lisa RomettyBoard director
DA
Dennis AusielloBoard director

Investors · 2

RA CapitalreportedBoston

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$60.3M disclosed across 1 round · 2025

▶$60.3MraisedNov 2025 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Talat ImranExecutive Officer, Director
  • Abraham BassanDirector
  • Vasudev Bailey, M.D.Director
  • Svai SanfordExecutive Officer
  • Mir HashimExecutive Officer
  • Jean-Luc ButelDirector
  • Lisa RomettyDirector
  • Mir ImranDirector
  • Dennis AusielloDirector
Offering amount
$60.3M
Amount sold
$60.3M
Sales commissions
$2.9M
Placement agents
Maxim Group LLC, H.C. Wainwright & Co, LLC
First sale
Oct 2025
Incorporated
Corporation, California, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$206.1Mvaluation at IPOAug 2021 · $11.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

2 people who came through Rani Therapeutics Holdings went on to found or lead other companies.

Mir ImranDirectorFounded Rani TherapeuticsTalat ImranExecutive Officer, DirectorFounded Rani Therapeutics

Frequently asked questions

What does Rani Therapeutics Holdings do?
Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for biologics and drugs, primarily through its proprietary RaniPill capsule platform, which comes in two configurations (RaniPill GO for up to 3 mg microtablet doses and RaniPill HC for up to 200µL liquid doses). The company is advancing a pipeline of oral therapeutic candidates internally and through collaborations with third-party biopharmaceutical companies, including RT-114 (a GLP-1/GLP-2 dual agonist for obesity) in Phase 1 trials and RT-117 (an antibody for hemophilia) in collaboration with Chugai Pharmaceutical.
Who are Rani Therapeutics Holdings's investors?
Rani Therapeutics Holdings's investors include InCube Ventures, RA Capital.
How much funding has Rani Therapeutics Holdings raised?
Rani Therapeutics Holdings has disclosed $60.3M raised across 1 round.
Where is Rani Therapeutics Holdings headquartered?
Rani Therapeutics Holdings is headquartered in San Jose, US.